검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Evolocumab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Primary Hyperlipidemia and Mixed Dyslipi |
Overview Indication | Atherosclerotic Cardiovascular Disease; Symptomatic Atherosclerosis |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | in tissues was verified by transcriptome sequencing |
MoA Biomarker | Biomarkers in Heterozygous Familial Hypercholesterolemia |
PK/PD Half-life | 17 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparative Effects of Emerging Lp(a)-Lowering Agents and PCSK9-Directed Therapies on Lipoprotein(a): A Network Meta-Analysis of Randomised Clinical Trials.. Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL-C lowering. We compared the efficacy and safety of emerging Lp(a)-targeted therapies (siRNAs, antisense oligonucleotides and an oral asse… |
Clinical Primary efficacy | ORR 33.3% |
Clinical ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03337698 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Evolocumab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Primary Hyperlipidemia and Mixed Dyslipi |
Overview Indication | Atherosclerotic Cardiovascular Disease; Symptomatic Atherosclerosis |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | in tissues was verified by transcriptome sequencing |
MoA Biomarker | Biomarkers in Heterozygous Familial Hypercholesterolemia |
PK/PD Half-life | 17 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparative Effects of Emerging Lp(a)-Lowering Agents and PCSK9-Directed Therapies on Lipoprotein(a): A Network Meta-Analysis of Randomised Clinical Trials.. Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL-C lowering. We compared the efficacy and safety of emerging Lp(a)-targeted therapies (siRNAs, antisense oligonucleotides and an oral asse… |
Clinical Primary efficacy | ORR 33.3% |
Clinical ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03337698 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교